APYX · XBRL financial data

Apyx Medical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (APYX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	27,711	48,517	44,510	52,349	48,102	52,844
Cost of goods and services sold	10,207	14,916	15,379	18,590	18,742	19,800
Gross profit	17,504	33,601	29,131	33,759	29,360	33,044
Research and development	3,920	4,321	4,544	4,844	5,080	3,373
Selling, general and administrative	11,687	18,617	20,484	22,198	18,858	15,803
Total operating expenses	37,587	48,049	52,693	53,710	48,205	39,490
Other operating income (expense)	479	(373)	509	622	(161)	92
Operating income (loss)	(20,083)	(14,448)	(23,562)	(17,259)	(18,845)	(6,446)
Interest income	—	—	—	921	1,606	1,108
Interest expense	46	10	15	2,478	5,907	5,589
Other income (expense)	674	(372)	651	(4,023)	(161)	—
Income tax expense (benefit)	(7,503)	380	367	(2,432)	252	270
Net income (loss)	(11,896)	(15,172)	(23,184)	(18,713)	(23,463)	(11,211)
Earnings per share, basic USD per share	(0.35)	(0.44)	(0.67)	(0.54)	(0.66)	(0.27)
Earnings per share, diluted USD per share	(0.35)	(0.44)	(0.67)	(0.54)	—	—
Weighted average shares, basic thousands of shares	34,212	34,332	34,516	34,622	35,542	41,095
Weighted average shares, diluted thousands of shares	34,212	34,332	34,516	34,622	—	—

Fiscal years (APYX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	41,915	30,870	10,192	43,652	31,741	31,740
Marketable securities	39,665	—	—	—	—	—
Accounts receivable	8,399	13,038	10,602	14,023	15,480	16,776
Inventory	4,051	6,778	11,797	9,923	7,564	8,602
Prepaid and other current assets	2,795	1,926	2,737	2,734	1,655	1,353
Total current assets	66,089	60,737	42,972	70,362	56,440	58,471
Property and equipment, net	6,541	6,575	6,761	1,915	1,987	2,371
Right-of-use asset	237	121	710	5,162	4,703	4,218
Total assets	74,111	68,721	51,775	79,240	64,842	66,840
Accounts payable	1,511	2,631	2,669	2,712	2,615	3,058
Accrued liabilities	7,278	10,287	8,928	9,661	7,751	8,214
Current portion of long-term debt	—	—	0	—	—	—
Total current liabilities	9,153	13,205	11,850	12,740	10,721	11,700
Long-term debt	—	—	0	33,185	33,893	34,849
Lease liability, non-current	129	0	470	4,896	4,483	4,051
Total liabilities	10,252	14,712	13,982	52,318	50,507	52,009
Retained earnings (accumulated deficit)	2,621	(12,551)	(35,735)	(54,448)	(77,911)	(89,122)
Total stockholders' equity	63,721	53,704	37,582	26,701	14,210	14,540
Total liabilities and equity	74,111	68,721	51,775	79,240	64,842	66,840
Common shares outstanding (cover page) thousands of shares	34,318	34,428	34,598	34,644	37,794	41,829

Fiscal years (APYX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(11,896)	(15,172)	(23,184)	(18,713)	(23,463)	(11,211)
Stock-based compensation	4,210	5,088	6,697	5,114	4,013	2,001
Depreciation and amortization	887	903	890	692	599	655
Net cash from operating activities	(16,066)	(10,449)	(20,280)	(5,249)	(18,047)	(8,001)
Purchases of property and equipment	581	723	1,010	533	722	1,114
Net cash from investing activities	(581)	(723)	(1,010)	6,734	(722)	(1,114)
Proceeds from long-term debt	—	—	0	43,474	0	—
Net cash from financing activities	(73)	24	217	32,166	6,745	9,580
Net change in cash	(16,897)	(11,045)	(20,678)	33,460	(11,911)	(1)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.